Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design

Platinum Compounds: a New Class of Potent Antitumour Agents

Barnett Rosenberg, Loretta Vancamp, James E. Trosko et al. · Nature · 1969 · 3.9K citations

Medicinal Chemistry, Medicine, New Class +4

Design of Organic Molecules with Large Two-Photon Absorption Cross Sections

Marius A. Albotǎ, David Beljonne, Jean‐Luc Brédas et al. · Science · 1998 · 2.2K citations

A Phase I and Pharmacological Study with Imidazolium-<b> <i>trans-</i> </b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

Jeany M. Rademaker-Lakhai, H.J.G.D. van den Bongard, Dick Pluim et al. · Clinical Cancer Research · 2004 · 820 citations · Full text

Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes

Robert E. Morris, Rhona Aird, Piedad del Socorro Murdoch et al. · Journal of Medicinal Chemistry · 2001 · 776 citations

Inorganic Chemistry, Medicinal Chemistry, Biochemistry +13

Classical and Non‐Classical Ruthenium‐Based Anticancer Drugs: Towards Targeted Chemotherapy

Wee Han Ang, Paul J. Dyson · European Journal of Inorganic Chemistry · 2006 · 621 citations · Full text

Ideal Scaffold, Pharmacotherapy, Pharmaceutical Chemistry +17